Dr. Menter was awarded £17,700 for his project on post transplantation-associated lymphoproliferative disorders (PTLD). A recent update was provided by Dr. Menter in April 2017 which we share below.
In this study, the aim was to characterise lymphomas arising in patients suffering from PTLD at the genetic levels. As this is a rare disease, the cohort of the University Hospital Basel, Switzerland was joined with the cohort of the Imperial College Healthcare NHS Trust, London in order to have a sufficient number of cases (total number of 50).
The research team investigated a large number of different genes involved both in potential pathways of lymphoma development, as well as genes which are important as indicators for new treatment options beyond standard chemotherapy, and those which have a predictive and prognostic value. For this, they used recently established cutting edge technologies of gene analysis (Next Generation Sequencing, NGS) which allow a both more cost-effective and more comprehensive approach than other techniques.
This important study of this rare type of lymphomas is the first analysing the mutational profile of PTLDs, and has both a therapeutic and a potential diagnostic impact.
Dr Menter says: “The support of the Lymphoma Research Trust helped us to retrieve and work up the patients’ biopsies and perform the genetic analyses. Furthermore, it also helped to cover the publication charges. The scientific publication of our work has been accepted by the British Journal of Haematology.”
Dr Jennifer Vidler, King’s College Hospital.
In July 2014, £7,718.76 was awarded to Dr Vidler who is investigating the gene expression of the Epstein-Barr Virus (EBV) and the host using real-time PCR assays in patients who have had a bone marrow transplant. She provided the following update in Dec 2016;
Our project looked at a selection of Epstein-Barr Virus (EBV) and host genes in the blood of patients who had undergone a bone marrow transplant. We used real-time polymerase chain reaction to investigate these genes and how their expression might be different in patients who went on to develop post-transplant lymphoproliferative disease (PTLD). Our research provided some interesting results that have led on to further research projects and the findings have been presented at the Clinical Virology Network meeting at the Microbiology Society Annual Meeting 2016.
Core grant to Haematology Trials Group.
In November 2015 the trustees awarded funding to the value of £268,104 to the Haematology Trials Group for three years from 2016 to 2018. This will support the next generation of national and international trials and facilitate the long-term assessment of treatment efficacy and treatment related toxicity. In this way the grant will contribute towards improvement of patient care, with the development and optimisation of therapy resulting in a reduction in morbidity and morality.
Dr. Kathy Till, University of Liverpool.
Funding of £6,000 was awarded to Dr. Till in May 2014 to continue her research into the role of chemokines and integrins in the localisation of B-cell non-Hodgkins Lymphomas (NHL). In 2015 she provided us with the following update;
The aim of the grants that we have received from the LRT were to identify the adhesion and motility factors involved in the distinctive distribution and localisation of the malignant lymphocytes of B cell non-Hodgkin’s lymphomas (B-NHL) in tissues. By doing this we expected that we might identify novel targets for therapy of lymphomas, many of which remain incurable despite the considerable advances in treatment. We have achieved this aim i.e. we have defined the factors involved in the tissue localisation of the malignant lymphocytes of B-NHL. In addition, we unexpectedly found that these factors were dependent on the location of the tumour, and not the sub-type of the lymphoma. We have published this work in an open access journal (Experimental Haematology and Oncology) and the paper is one of the most viewed articles in the journal; it can be accessed via the following link – http://ehoonline.biomedcentral.com/articles/10.1186/s40164-015-0004-3 We are currently involved in investigating how these factors affect the movement and adhesion of lymphoma cell lines so that we can get a better understanding of the interplay between these molecules. We anticipate that this will enable us to define which of these factors are the most promising with regard to designing new therapeutic interventions, and will thereby enable the clinicians to use personalised treatment strategies which are more likely to achieve their desired result.
Dr. Jessica Brady, Guy’s and St. Thomas’ Hospital.
Funding of £10,000 was also awarded in July 2014 to Dr. Brady’s project which is undertaking an evaluation of deep inspiration breath-hold technique to reduce toxicity of mediastinal radiotherapy for lymphoma.